309 related articles for article (PubMed ID: 37857527)
21. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
22. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
Gao W; Liu Q; Zhou Y; Yang M; Yu Y
Technol Cancer Res Treat; 2023; 22():15330338231206705. PubMed ID: 37927008
[TBL] [Abstract][Full Text] [Related]
23. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
24. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
25. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
Sonehara K; Tateishi K; Araki T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Oncology; 2021; 99(5):271-279. PubMed ID: 33631764
[TBL] [Abstract][Full Text] [Related]
26. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
27. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
Blum SM; Rouhani SJ; Sullivan RJ
Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
[TBL] [Abstract][Full Text] [Related]
28. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
29. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
30. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
[TBL] [Abstract][Full Text] [Related]
31. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
32. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
33. Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma.
Cao R; Wu C; Lv Y; Xu S; Li C; Yin F; Li J
Oncol Lett; 2023 Feb; 25(2):55. PubMed ID: 36644142
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
35. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
36. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
[TBL] [Abstract][Full Text] [Related]
37. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Hsu ML; Murray JC; Psoter KJ; Zhang J; Barasa D; Brahmer JR; Ettinger DS; Forde PM; Hann CL; Lam VK; Levy B; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Anagnostou V; Naidoo J; Feliciano JL
Oncologist; 2022 Nov; 27(11):971-981. PubMed ID: 35972337
[TBL] [Abstract][Full Text] [Related]
40. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]